September 2011, Vol 4, No 5

Introduction

In Search of Stakeholder Collaboration to Stem the Cardiometabolic Epidemic
Dalia Buffery, MA, ABD

Original Research

Obesity in the Workplace: Impact on Cardiovascular Disease, Cost, and Utilization of Care
Alberto M. Colombi, MD, MPH
; G. Craig Wood, MS
Stakeholder Perspective by Wayne M. Lednar, MD, PhD

Clinical

A Call to Action: Responding to the Future Forecasting of Cardiovascular Disease in America
Robert Lee Page ii, PharmD, MSPH, FAHA, FCCP, FASCcP, FASHP, BCPS
; Vahram Ghushchyan, PhD
; Kavita Nair, PhD
Stakeholder Perspective by James T. Kenney, RPh, MBA
Atypical Antipsychotics and Metabolic Syndrome in Patients with Schizophrenia: Risk Factors, Monitoring, and Healthcare Implications
Henry J. Riordan, PhD
; Paola Antonini, MD, PhD
; Michael F. Murphy, MD, PhD
Stakeholder Perspective by Atheer A. Kaddis, PharmD
Current Therapies and Emerging Drugs in the Pipeline for Type 2 Diabetes
Quang T. Nguyen, DO
; Karmella T. Thomas, BS, RD
; Katie B. Lyons, MS II
; Loida D. Nguyen, PharmD, BCBS
; Raymond A. Plodkowski, MD
Stakeholder Perspective by James V. Felicetta, MD
Lipid Management in Patients with Type 2 Diabetes
Marsha J. Daniel, PharmD, cPh, CDE
Stakeholder Perspective by Gary M. Owens, MD